Selected Protease Inhibitors; Cobicistat/CYP3A4 Inducers Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may speed up how quickly your liver processes boceprevir, cobicistat, nirmatrelvir, and telaprevir.Also, your medicine may slow down how quickly your liver processes carbamazepine.
What might happen:
The amount of boceprevir, cobicistat, nirmatrelvir, or telaprevir in your blood may decrease and it may not work as well.Also, your blood levels of carbamazepine may increase and cause more side effects than expected.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know if you are taking these medicines together, if you have taken them in the previous two weeks, or if you stop taking them. Your doctor may want to adjust your medicines.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Victrelis (boceprevir) US prescribing information. Schering Corporation January, 2017.
- 2.Tybost (cobicistat) EMA summary of product characteristics. Gilead Sciences Limited May, 2014.
- 3.Tybost (cobicistat) US prescribing information. Gilead Sciences, Inc. September, 2021.
- 4.Paxlovid (nirmatrelvir tablets and ritonavir tablets) US prescribing information. Pfizer Inc. May, 2023.
- 5.Incivek (telaprevir) US prescribing information. Vertex Pharmaceuticals Incorporated October, 2013.
- 6.Tegretol (carbamazepine) US prescribing information. Novartis Pharmaceuticals Corporation September, 2023.
- 7.Thorn CF, Leckband SG, Kelsoe J, Leeder JS, MAller DJ, Klein TE, Altman RB. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics 2011 Dec;21(12):906-10.
- 8.Cox DS, Van Eyck L, Pawlak S, Beckerman B, Linn C, Ginman K, Cha YT, LaBadie RR, Shi H, Damle B. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults. Br J Clin Pharmacol 2023 May 15.
- 9.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 10.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.